20:05:15 EST Wed 11 Nov 2026
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:VKTX from 2025-11-12 to 2026-11-11 - 35 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-11-09 07:05U:VKTXNews ReleaseViking Therapeutics Announces Two Poster Presentations at ObesityWeek(TM) 2026
2026-11-03 16:30U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences
2026-11-03 09:00U:VKTXNews ReleasePeptide Therapies Are Changing the Future of Medicine - And the Market Could Reach $335 Billion
2026-10-28 16:05U:VKTXNews ReleaseViking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-10-21 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
2026-10-14 07:05U:VKTXNews ReleaseViking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
2026-10-06 07:05U:VKTXNews ReleaseViking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity
2026-09-28 16:30U:VKTXNews ReleaseViking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
2026-09-24 07:05U:VKTXNews ReleaseViking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes
2026-09-23 16:32U:VKTXNews ReleaseViking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes
2026-09-22 07:05U:VKTXNews ReleaseViking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
2026-09-02 16:05U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences
2026-07-29 16:05U:VKTXNews ReleaseViking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-07-23 07:05U:VKTXNews ReleaseViking Therapeutics Appoints Dorothy Gemmell to Board of Directors
2026-07-22 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
2026-06-24 07:05U:VKTXNews ReleaseViking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
2026-06-11 07:05U:VKTXNews ReleaseViking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
2026-05-21 07:05U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences
2026-05-13 08:30U:VKTXNews ReleaseNext-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
2026-05-12 07:05U:VKTXNews ReleaseViking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
2026-05-05 07:05U:VKTXNews ReleaseViking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026
2026-04-29 16:05U:VKTXNews ReleaseViking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-04-23 06:15U:VKTXNews ReleaseThe Longevity Trade Is No Longer a Buzzword - It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
2026-04-22 16:35U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
2026-04-10 07:30U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences
2026-03-26 07:05U:VKTXNews ReleaseViking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
2026-03-05 16:03U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences
2026-02-11 16:05U:VKTXNews ReleaseViking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
2026-02-04 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
2026-01-12 07:00U:VKTXNews ReleaseViking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
2026-01-08 07:00U:VKTXNews ReleaseViking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
2026-01-07 07:00U:VKTXNews ReleaseViking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer
2026-01-05 16:03U:VKTXNews ReleaseViking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-11-25 16:05U:VKTXNews ReleaseViking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
2025-11-19 02:55U:VKTXNews ReleaseViking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735